The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 33, Issue 2, 2002, Pages 280-287

  Moolasart, Pikul ^a   Likanonsakul, Sirirat ^a  

^a Bamrasnaradura Infectious Disease Institute   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; THAILAND; TREATMENT OUTCOME; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 0036599585     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Anonymous. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21.
2. Bardsley-Elliot A, Plosder GL. Nelfinavir: an update on its use in HTV Infection. Drugs 2000; 59: 581-620.
3. Carey VJ, Yong FH, Frenkel LM, McKinney Jr RE. Pediatric AIDS prognosis using somatic growth velocity. AIDS 1998; 12: 1361-9.
4. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HTV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280: 78-86.
5. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1-10.
6. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents. MMWR 1998; 47(RR-5): 43-65.
7. Dankner WM, Lindsey JC, Levin MJ, The Pediatric ACTG Protocol Teams. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20: 40-8.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998; 47(RR-5): 43-82.
9. Ellaurie M, Burns ER, Bernstein LJ, Shah K, Rubinstein A. Thrombocytopenia and human immunodeficiency virus in children. Pediatrics 1988; 82: 905-8.
10. Ellaurie M, Burns ER, Rubinstein A. Hematologic manifestations in pediatric HTV infection: severe anemia as a prognostic factor. Am J Pediatr Hematol Oncol 1990; 12: 449-53.
11. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999; 13: 1653-8.
12. Hammer SM, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90.
13. Hammer SM, Squires K, Hughes M, et al. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected person with CD4 counts less than or equal to 200 per cubic millimeter. N Engl J Med 1997; 337: 725-33.
14. th Conference on Antiviral Research, Apr 6-11, 1994.
15. Hoffmann F, Notheis G, Wintergerst U, et al. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. Pediatr Infect Dis J 2000; 19: 47-51.
16. Jakob-Solder B. Antiretroviral therapy in children. Wien Med Wochenschr 1998; 148: 539-46.
17. Karpatkin S. HIV-1-related thrombocytopenia. Hematolol Oncol Clin North Am 1990; 4: 193-218.
18. Mann M, Piazza-Hepp T, Koller E, Struble K, Murray J. Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the Food and Drug Administration. AIDS Patient Care STDS 1999; 13: 287-95.
19. McKinney RE, Robertson WR, the Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr 1993; 123: 579-82.
20. rd ed. Maryland: Williams & Wilkins, 1998: 363-82.
21. rd ed; Maryland: Williams & Wilkins, 1998: 427-42.
22. Mueller BU, Sleasman J, Nelson RP Jr, et al. A phase I/II study of the protease inhibitors in children with HIV infection. Pediatrics 1998; 102: 101-9.
23. Nadal D, Steiner F, Cheseaux JJ, et al. Long-term responses to treatment including ritonavir or nelfmavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. Infection 2000; 28: 287-96.
24. Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892. Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides. Am J Med 1990; 88: 16S-19S.
25. Perry CM, Benfield P. Nelfinavir. Drugs 1997; 54: 81-7.
26. Precious HM, Gunthard HF, Wong JK, et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000; 14: 31-6.
27. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J AIDS 2001; 26: 315-9.
28. Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatment for HIV-1. Control Clin Trials 2001; 22: 139-41.
29. Tremblay C, Merrill DP, Chou TC, Hirsch MS. Interactions among combinations of three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. J AIDS 1999; 22: 430-6.